Back to Search Start Over

Period 2 mutation accelerates ApcMin/+ tumorigenesis.

Authors :
Wood PA
Yang X
Taber A
Oh EY
Ansell C
Ayers SE
Al-Assaad Z
Carnevale K
Berger FG
Peña MM
Hrushesky WJ
Source :
Molecular cancer research : MCR [Mol Cancer Res] 2008 Nov; Vol. 6 (11), pp. 1786-93.
Publication Year :
2008

Abstract

Colorectal cancer risk is increased in shift workers with presumed circadian disruption. Intestinal epithelial cell proliferation is gated throughout each day by the circadian clock. Period 2 (Per2) is a key circadian clock gene. Per2 mutant (Per2(m/m)) mice show an increase in lymphomas and deregulated expression of cyclin D and c-Myc genes that are key to proliferation control. We asked whether Per2 clock gene inactivation would accelerate intestinal and colonic tumorigenesis. The effects of PER2 on cell proliferation and beta-catenin were studied in colon cancer cell lines by its down-regulation following RNA interference. The effects of Per2 inactivation in vivo on beta-catenin and on intestinal and colonic polyp formation were studied in mice with Per2 mutation alone and in combination with an Apc mutation using polyp-prone Apc(Min/+) mice. Down-regulation of PER2 in colon cell lines (HCT116 and SW480) increases beta-catenin, cyclin D, and cell proliferation. Down-regulation of beta-catenin along with Per2 blocks the increase in cyclin D and cell proliferation. Per2(m/m) mice develop colonic polyps and show an increase in small intestinal mucosa beta-catenin and cyclin D protein levels compared with wild-type mice. Apc(Min/+)Per2(m/m) mice develop twice the number of small intestinal and colonic polyps, with more severe anemia and splenomegaly, compared with Apc(Min/+) mice. These data suggest that Per2 gene product suppresses tumorigenesis in the small intestine and colon by down-regulation of beta-catenin and beta-catenin target genes, and this circadian core clock gene may represent a novel target for colorectal cancer prevention and control.

Details

Language :
English
ISSN :
1541-7786
Volume :
6
Issue :
11
Database :
MEDLINE
Journal :
Molecular cancer research : MCR
Publication Type :
Academic Journal
Accession number :
19010825
Full Text :
https://doi.org/10.1158/1541-7786.MCR-08-0196